Marcos Da Silva Freire

Dr. Marcos Da Silva Freire

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
PEPaula de Almeida Estevam
Paula de Almeida Estevam
JCJordana Grazziela Alves Coelho-dos-Reis
Jordana Grazziela Alves Coelho-dos-Reis
VPVanessa Peruhype-Magalhães
Vanessa Peruhype-Magalhães
GVGabriela Villela-Rezende
Gabriela Villela-Rezende
OMOlindo Martins-filho
Olindo Martins-filho
The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.

1 January 2007 in Virology Journal
Verified
Journal Article
Open access
PDF file
MBMyrna Cristina Bonaldo
Myrna Cristina Bonaldo
SMSamanta M Mello
Samanta M Mello
GTGisela Freitas Trindade
Gisela Freitas Trindade
ARAymara A Rangel
Aymara A Rangel
ADAdriana S Duarte
Adriana S Duarte
RGRicardo Galler
Ricardo Galler
The yellow fever virus, a member of the genus Flavivirus, is an arthropod-borne pathogen causing severe disease in humans. The attenuated yellow fever 17D virus strain has been used for human vaccination for 70 years and has several characteristics that are desirable for the development of new, live attenuated vaccines. We described here a methodology to construct a viable, and immunogenic recombinant yellow fever 17D virus expressing a green fluorescent protein variant (EGFP). This approach took into account the presence of functional motifs and amino acid sequence conservation flanking the E and NS1 intergenic region to duplicate and fuse them to the exogenous gene and thereby allow the correct processing of the viral polyprotein precursor.

1 February 2020 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
SMSheeba Murad
Sheeba Murad
SFSebastian Fuller
Sebastian Fuller
JMJonathan Menary
Jonathan Menary
CMCathy Moore
Cathy Moore
EPElizabeth Pinneh
Elizabeth Pinneh
JMJulian K-C Ma
Julian K-C Ma

7 February 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
STStephen Tottey
Stephen Tottey
YSYoko Shoji
Yoko Shoji
RJR. Mark Jones
R. Mark Jones
JCJessica A. Chichester
Jessica A. Chichester
BGBrian J. Green
Brian J. Green
VYVidadi Yusibov
Vidadi Yusibov
Yellow fever (YF) is a viral disease transmitted by mosquitoes and endemic mostly in South America and Africa with 20–50% fatality. All current licensed YF vaccines, including YF-Vax® (Sanofi-Pasteur, Lyon, France) and 17DD-YFV (Bio-Manguinhos, Rio de Janeiro, Brazil), are based on live attenuated virus produced in hens’ eggs and have been widely used. The YF vaccines are considered safe and highly effective. However, a recent increase in demand for YF vaccines and reports of rare cases of YF vaccine-associated fatal adverse events have provoked interest in developing a safer YF vaccine that can be easily scaled up to meet this increased global demand. To this point, we have engineered the YF virus envelope protein (YFE) and transiently expressed it in Nicotiana benthamiana as a stand-alone protein (YFE) or as fusion to the bacterial enzyme lichenase (YFE-LicKM). Immunogenicity and challenge studies in mice demonstrated that both YFE and YFE-LicKM elicited virus neutralizing (VN) antibodies and protected over 70% of mice from lethal challenge infection. Furthermore, these two YFE-based vaccine candidates induced VN antibody responses with high serum avidity in nonhuman primates and these VN antibody responses were further enhanced after challenge infection with the 17DD strain of YF virus. These results demonstrate partial protective efficacy in mice of YFE-based subunit vaccines expressed in N. benthamiana. However, their efficacy is inferior to that of the live attenuated 17DD vaccine, indicating that formulation development, such as incorporating a more suitable adjuvant, may be required for product development.

1 September 2006 in Biologicals
Verified
Journal Article
Closed access
RMRenato Sergio Marchevsky
Renato Sergio Marchevsky
MLMaria da Luz Leal
Maria da Luz Leal
AHAkira Homma
Akira Homma
ECEvandro S.F. Coutinho
Evandro S.F. Coutinho
LCLuis A.B. Camacho
Luis A.B. Camacho
MFMarcos Da Silva Freire
Marcos Da Silva Freire

20 November 2020 in Journal of Medical Primatology
Verified
Journal Article
Closed access
PDF file
AFAndré Tavares da Silva Fernandes
André Tavares da Silva Fernandes
SMSilvia Bahadian Moreira
Silvia Bahadian Moreira
LGLuciane Pinto Gaspar
Luciane Pinto Gaspar
MSMarisol Simões
Marisol Simões
ACAna Carolina dos Reis Albuquerque Cajaraville
Ana Carolina dos Reis Albuquerque Cajaraville
MFMarcos Da Silva Freire
Marcos Da Silva Freire